These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7517168)

  • 21. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
    Lanier LL; Benike CJ; Phillips JH; Engleman EG
    J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity.
    Park KG; Heys SD; Murray JB; Hayes PD; Ashby JA; Franks CR; Eremin O
    Cancer Immunol Immunother; 1992; 35(1):53-8. PubMed ID: 1611623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.
    Nishikawa K; Saito S; Morii T; Hamada K; Ako H; Narita N; Ichijo M; Kurahayashi M; Sugamura K
    Int Immunol; 1991 Aug; 3(8):743-50. PubMed ID: 1716974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.
    Janssen RA; Buter J; Straatsma E; Heijn AA; Sleijfer DT; de Vries EG; Mulder NH; The TH; de Leij L
    Cancer Immunol Immunother; 1993; 36(3):198-204. PubMed ID: 8439981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different sensitivity to interleukin 4 of interleukin 2- and interferon alpha-induced CD69 antigen expression in human resting NK cells and CD3+, CD4-, CD8- lymphocytes.
    Gerosa F; Tommasi M; Carra G; Gandini G; Tridente G; Benati C
    Cell Immunol; 1992 May; 141(2):342-51. PubMed ID: 1533569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.
    Castello G; Comella P; Manzo T; Napolitano M; Parziale AP; Galati MG; Daponte A; Casaretti R; Celentano E; Comella G
    Melanoma Res; 1993 Feb; 3(1):43-9. PubMed ID: 8471836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural killer activity of lymphocytes infiltrating human lung cancers following preoperative systemic recombinant interleukin 2.
    Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun S; Holmes C; Golub SH
    Arch Surg; 1987 Dec; 122(12):1446-50. PubMed ID: 3500691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.
    Vlasveld LT; Hekman A; Vyth-Dreese FA; Rankin EM; Scharenberg JG; Voordouw AC; Sein JJ; Dellemijn TA; Rodenhuis S; Melief CJ
    Br J Cancer; 1993 Sep; 68(3):559-67. PubMed ID: 8353046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of tyrosine kinase inhibition in CD69 antigen expression and lytic activity induced by rIL-2, rIL-12, and rIFN-alpha in human NK cells.
    Gerosa F; Tommasi M; Benati C; Gandini G; Libonati M; Tridente G; Carra G; Trinchieri G
    Cell Immunol; 1993 Sep; 150(2):382-90. PubMed ID: 8103709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial.
    Truitt RL; Piaskowski V; Kirchner P; McOlash L; Camitta BM; Casper JT
    J Immunother (1991); 1992 May; 11(4):274-85. PubMed ID: 1599913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular source of soluble interleukin 2 receptors in serum of mice after recombinant interleukin 2 administration.
    Wagner DK; Wong HL; Gately MK; Nelson DL
    Cytokine; 1990 Sep; 2(5):337-43. PubMed ID: 1715768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine.
    McMahon DK; Armstrong JA; Huang XL; Rinaldo CR; Gupta P; Whiteside TL; Pazin GJ; Tripoli C; Ho M
    AIDS; 1994 Jan; 8(1):59-66. PubMed ID: 8011237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
    Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
    J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell populations in the human early pregnancy decidua: natural killer activity and response to interleukin-2 of CD56-positive large granular lymphocytes.
    Ferry BL; Starkey PM; Sargent IL; Watt GM; Jackson M; Redman CW
    Immunology; 1990 Aug; 70(4):446-52. PubMed ID: 1697563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S; Naruo K; Shiho O; Tsukamoto K
    Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
    Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
    Farace F; Mathiot C; Brandely M; Tursz T; Dorval T; Pouillart P; Triebel F; Hercend T; Fridman WH
    Clin Exp Immunol; 1990 Nov; 82(2):194-9. PubMed ID: 2122928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.